A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus

Virus Research

Volumn 179, Issue 1, 2014, Pages 119-124

  Qi, Yuhua ^a   Fan, Huan ^a   Qi, Xian ^a   Zhu, Zheng ^a   Guo, Xiling ^a   Chen, Yin ^a   Ge, Yiyue ^a   Zhao, Kangchen ^a   Wu, Tao ^a   Li, Yan ^a   Shan, Yunfeng ^a   Zhou, Minghao ^a   Shi, Zhiyang ^a   Wang, Hua ^a   Cui, Lunbiao ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Avian influenza A (H7N9) virus; E120V mutation; NAIs resistance; Pyrosequencing

Indexed keywords

SIALIDASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA VIRUS; CASE REPORT; FEMALE; HUMAN; INFLUENZA VIRUS A H7N9; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

AVES; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

AVIAN INFLUENZA A (H7N9) VIRUS; E120V MUTATION; NAIS RESISTANCE; PYROSEQUENCING;

ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; CHINA; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS;

EID: 84892796967     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.10.026     Document Type: Article

References (25)

1. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366(9492):1175-1181.
2. Interim Guidance on the Use of Antiviral Agents for Treatment of Human Infections with Avian Influenza A (H7N9) 2013, Centers for Disease Control Prevention (CDC), Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm.
3. Chan P.K. A review on human influenza A H5N1 infections in Hong Kong. Sci. China C: Life Sci. 2009, 52(5):412-418.
4. Cheng V.C., Chan J.F., Wen X., Wu W.L., Que T.L., Chen H., Chan K.H., Yuen K.Y. Infection of immunocompromised patients by avian H9N2 influenza A virus. J. Infect. 2011, 62(5):394-399.
5. Dapat C., Suzuki Y., Saito R., Kyaw Y., Myint Y.Y., Lin N., Oo H.N., Oo K.Y., Win N., Naito M., Hasegawa G., Dapat I.C., Zaraket H., Baranovich T., Nishikawa M., Saito T., Suzuki H. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg. Infect. Dis. 2010, 16(3):493-496.
6. DeVries A., Wotton J., Lees C., Boxrud D., Uyeki T., Lynfield R. Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection. Influenza Other Respi. Viruses 2012, 6(6):e85-e88.
7. Deyde V.M., Nguyen T., Bright R.A., Balish A., Shu B., Lindstrom S., Klimov A.I., Gubareva L.V. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob. Agents Chemother. 2009, 53(3):1039-1047.
8. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301(10):1034-1041.
9. Ferraris O., Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 2008, 41(1):13-19.
10. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., Kuiken T., Rimmelzwaan G.F., Schutten M., Van Doornum G.J., Koch G., Bosman A., Koopmans M., Osterhaus A.D. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(5):1356-1361.
11. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., Chen J., Jie Z., Qiu H., Xu K., Xu X., Lu H., Zhu W., Gao Z., Xiang N., Shen Y., He Z., Gu Y., Zhang Z., Yang Y., Zhao X., Zhou L., Li X., Zou S., Zhang Y., Yang L., Guo J., Dong J., Li Q., Dong L., Zhu Y., Bai T., Wang S., Hao P., Yang W., Han J., Yu H., Li D., Gao G.F., Wu G., Wang Y., Yuan Z., Shu Y. Human Infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368(20):1888-1897.
12. Graitcer S.B., Gubareva L., Kamimoto L., Doshi S., Vandermeer M., Louie J., Waters C., Moore Z., Sleeman K., Okomo-Adhiambo M., Marshall S.A., St George K., Pan C.Y., LaPlante J.M., Klimov A., Fry A.M. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis. 2011, 17(2):255-257.
13. Hu Y., Lu S., Song Z., Wang W., Hao P., Li J., Zhang X., Yen H.L., Shi B., Li T., Guan W., Xu L., Liu Y., Wang S., Tian D., Zhu Z., He J., Huang K., Chen H., Zheng L., Li X., Ping J., Kang B., Xi X., Zha L., Li Y., Zhang Z., Peiris M., Yuan Z. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013, 381(9885):2273-2279.
14. Hurt A.C., Holien J.K., Parker M.W., Barr I.G. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69(18):2523-2531.
15. Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010, 6(7):e1001005.
16. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437(7062):1108.
17. Moscona A. Medical management of influenza infection. Annu. Rev. Med. 2008, 59:397-413.
18. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 2012, 17(1 Pt B):159-173.
19. Okomo-Adhiambo M., Demmler-Harrison G.J., Deyde V.M., Sheu T.G., Xu X., Klimov A.I., Gubareva L.V. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 2010, 54(5):1834-1841.
20. Ostrowsky B., Huang A., Terry W., Anton D., Brunagel B., Traynor L., Abid S., Johnson G., Kacica M., Katz J., Edwards L., Lindstrom S., Klimov A., Uyeki T.M. Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA, 2003. Emerg. Infect. Dis. 2012, 18(7):1128-1131.
21. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52(9):3284-3292.
22. Simon P., Holder B.P., Bouhy X., Abed Y., Beauchemin C.A., Boivin G. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J. Clin. Microbiol. 2011, 49(2):715-717.
23. Tweed S.A., Skowronski D.M., David S.T., Larder A., Petric M., Lees W., Li Y., Katz J., Krajden M., Tellier R., Halpert C., Hirst M., Astell C., Lawrence D., Mak A. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 2004, 10(12):2196-2199.
24. Number of Confirmed Human Cases for Avian Influenza A (H7N9) Reported to WHO-Update 2013, World Health Organization, World Health Organization. http://www.who.int/influenza/human_animal_interface/influenza_h7n9/06_ReportWebH7N9Number.pdf.
25. Real-time RT-PCR Protocol for the Detection of Avian Influenza A (H7N9) Virus 2013, World Health Organization, World Health Organization. http://www.who.int/influenza/gisrs_laboratory/cnic_realtime_rt_pcr_protocol_a_h7n9.pdf.